{
    "clinical_study": {
        "@rank": "111019", 
        "arm_group": [
            {
                "arm_group_label": "Continuous Glucose Monitoring Group", 
                "arm_group_type": "Experimental", 
                "description": "Continuous Glucose Monitoring  Group:\nDifferent methods of blood glucose monitoring between groups, and this group will use real-time continuous glucose monitoring system with alarm limits\uff08high and low limit is 10 mmol/L and 8 mmil/L , respectively ) up to  five days for glucose control, the target mean glucose level is between 8 and 10 mmol/L."
            }, 
            {
                "arm_group_label": "Conventional Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Conventional Group\uff1a\nDifferent methods of blood glucose monitoring between groups, and this group will use finger prick blood glucose measurements for glucose control with the same target mean glucose level of 8 -10 mmol/L. Patients also wear real-time continuous glucose monitoring system to collect glucose measurements. The values of real-time continuous glucose monitoring system are blinded to investigator and patients."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the effect of real-time continuous glucose\n      monitoring system on glucose control and outcomes of critically ill patients."
        }, 
        "brief_title": "Effect of Real-time Continuous Glucose Monitoring on Glucose Control and Outcomes of Critically Ill Patients", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hyperglycemia", 
        "condition_browse": {
            "mesh_term": [
                "Critical Illness", 
                "Hyperglycemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Real-time continuous glucose monitoring system  has shown great accuracy and feasibility in\n      critically ill patients. However, its impact on glucose control and outcomes has  nearly\n      unknown. Thus, Investigators designed this study to evaluate the effect of real-time\n      continuous glucose monitoring system on glucose control and outcomes of critically ill\n      patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  More than 18 years old male or female;\n\n               -  Expected  ICU stays longer than 72 hours;\n\n                    -  Glucose level more than 8 mmol/L when enrolls in the ICU;\n\n                         -  Patients or their legal surrogates have signed the informed consent.\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women;\n\n               -  ICU stays less than 72 hours;\n\n                    -  Usage of real-time continuous glucose monitoring system  is considered as a\n                       contraindication."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "144", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01992965", 
            "org_study_id": "CGM-ky0521"
        }, 
        "intervention": {
            "arm_group_label": [
                "Continuous Glucose Monitoring Group", 
                "Conventional Group"
            ], 
            "description": "Finger prick blood glucose in conventional group versus real-time continuous glucose monitoring system of continuous glucose monitoring group", 
            "intervention_name": "Different methods of blood glucose monitoring between groups", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "continuous glucose monitoring\uff1b", 
            "critically ill;"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "location": {
            "contact": {
                "email": "kang_yan_123@163.com", 
                "last_name": "Yan Kang, MD", 
                "phone": "028-85422508"
            }, 
            "facility": {
                "address": {
                    "city": "Chengdu", 
                    "country": "China", 
                    "state": "Sichuan", 
                    "zip": "610000"
                }, 
                "name": "Intensive care unit of West China Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Yan Kang, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Yan-yan Zuo, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mei-zhu Lu, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Real-time Continuous Glucose Monitoring on Glucose Control and Outcomes of Critically Ill Patients", 
        "overall_contact": {
            "email": "kang_yan_123@163.com", 
            "last_name": "Yan Kang, MD", 
            "phone": "86-028-85422508"
        }, 
        "overall_contact_backup": {
            "email": "zyyan21@163.com", 
            "last_name": "Yan-yan Zuo, MM", 
            "phone": "86-028-85422506"
        }, 
        "overall_official": {
            "affiliation": "West China Hospital", 
            "last_name": "Yan Kang, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Glycemic Control Measures including: Percentage of target blood glucose levels (defined as between 8mmol/L and 10mmol/L);  Time of hyperglycemia (defined as >10mmol/L);  Hypoglycemia rate (defined as < 2.2mmol/L); Glucose lability index", 
            "safety_issue": "No", 
            "time_frame": "Glycemic control measures will be assessed up to five days."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01992965"
        }, 
        "responsible_party": {
            "investigator_affiliation": "West China Hospital, Sichuan University", 
            "investigator_full_name": "Kang Yan", 
            "investigator_title": "Director of Intensive Care Unit", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Prognosis Measures including:  Duration of mechanical ventilation\uff1bTime of ICU stay; Time of hospital stay; 28 days - mortality rate", 
                "safety_issue": "No", 
                "time_frame": "All the participants will be followed for the duration of hospital stay or 28 days."
            }, 
            {
                "measure": "Cost", 
                "safety_issue": "No", 
                "time_frame": "Cost associated with glucose monitoring"
            }
        ], 
        "source": "West China Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kang Yan", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}